Brickell Biotech Inc., of Boulder, Colo., completed its merger with Vical Inc., of San Diego, following approval by Vical's stockholders. Brickell commenced trading Tuesday on Nasdaq under the ticker BBI, with shares closing at $4.69. Vical contributes about $35 million to the combined company in addition to a research and development financing arrangement with Novaquest Capital Management that provides $25 million in funding.